Skip to main content
. 2020 Mar 6;12(3):612. doi: 10.3390/cancers12030612

Table 5.

Characteristics of the AVERT and CASSINI trials.

Study Characteristics AVERT CASSINI
Intervention Apixaban 2 × 2.5 mg/d Rivaroxaban 10 mg/d
Type of cancer Lymphoma 25%, gynecologic 26%, pancreas 13%, lung 10% Pancreas 33%, upper GI 21%, lung 15%, lymphoma 7%
Outcome definition Symptomatic or incidental VTE Symptomatic or incidental VTE or VTE death *
VTE rate in control group 10.2% 8.8%
Mortality in control group 9.8% 23.8%

* Systematic DVT screening, VTE: venous thromboembolism.